Trademark: 90406176
Word
PDMO
Status
Registered
Status Code
700
Status Date
Tuesday, November 29, 2022
Serial Number
90406176
Registration Number
6909412
Registration Date
Tuesday, November 29, 2022
Mark Type
4000
Filing Date
Wednesday, December 23, 2020
Published for Opposition
Tuesday, September 13, 2022

Trademark Owner History
Sterling Pharma Solutions Limited - Original Registrant

Classifications
40 Custom manufacture of pharmaceuticals; processing of pharmaceuticals, namely treatment in the nature of chemical processing of chemical, biochemical and pharmaceutical products for third parties; custom manufacturing services in the nature of processing of pharmaceutical preparations; processing of pharmaceutical preparations, assembly of products for others, namely, processing of pharmaceuticals, medicines, and biological preparations to the order and specification of others; treatment in the nature of chemical processing of chemical, biochemical and pharmaceutical products for third parties; treatment of materials, namely, pharmaceutical, biologic, and chemical products and their components used in the manufacture of pharmaceuticals, biotherapeutic products, and biopharmaceuticals; treatment and destruction of pharmaceutical waste; information, advice and consultancy services in relation to the aforesaid services
5 Pharmaceuticals, namely, psychotropics, antihelmintics, anti-infectives, lipid lowering agents, inducers of erections, induction agents, neuromuscular blocking agents, sedatives, anti-cancer medication, anti-inflammatories, anti-fungals, anti-bacterials, anti-spasmodics, appetite stimulants, bronchodilators, appetite suppressants, anti-convulsives, neuroprotective drugs, anti-anxiety medication, anti-depressants, anti-ischemics, anti-psychotics; pharmaceutical preparations for treating diabetes, ear, nose and throat disorders, epilepsy, genetic disorders, hematological disorders, hormonal disorders, infectious diseases, lymphoma, metabolic disorders, mouth and dental disorders, musculoskeletal disorder, non-malignant disorder, nutritional disorders, pain, rare ophthalmological diseases, rare cancers, rare infectious diseases, rare genetic diseases, rare respiratory diseases, rare central nervous system diseases, rare gastrointestinal diseases, rare immunological diseases, rare cardiovascular diseases, rare dermatological diseases, rare urinary system and sex hormone diseases, rare womens health diseases, and rare ear, nose, and throat diseases; Pharmaceuticals, namely, pharmaceutical preparations and substances for the treatment of viral, infectious, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders for medical or veterinary purposes; vaccines; medicine for treating diabetes, ear, nose and throat disorders, epilepsy, genetic disorders, hematological disorders, hormonal disorders, infectious diseases, lymphoma, metabolic disorders, mouth and dental disorders, musculoskeletal disorder, non-malignant disorder, nutritional disorders, pain, rare ophthalmological diseases, rare cancers, rare infectious diseases, rare genetic diseases, rare respiratory diseases, rare central nervous system diseases, rare gastrointestinal diseases, rare immunological diseases, rare cardiovascular diseases, rare dermatological diseases, rare urinary system and sex hormone diseases, rare womens health diseases, and rare ear, nose, and throat diseases; chemical preparations for use in the pharmaceutical industry, namely for treating diabetes, ear, nose and throat disorders, epilepsy, genetic disorders, hematological disorders, hormonal disorders, infectious diseases, lymphoma, metabolic disorders, mouth and dental disorders, musculoskeletal disorder, non-malignant disorder, nutritional disorders, pain, rare ophthalmological diseases, rare cancers, rare infectious diseases, rare genetic diseases, rare respiratory diseases, rare central nervous system diseases, rare gastrointestinal diseases, rare immunological diseases, rare cardiovascular diseases, rare dermatological diseases, rare urinary system and sex hormone diseases, rare womens health diseases, rare ear, nose, and throat diseases, animal health disorders, cardiovascular diseases and disorders, central nervous system disorders, dermatologic disorders, endocrine system disorders, gastrointestinal diseases, genito urinary system and sex hormone imbalances, male health disorders, women's health disorders, mental health disorders, musculoskeletal disorders, renal disorders, cancer, ophthalmic disorders, renal diseases, respiratory diseases, trauma and injury
1 Active chemical ingredients for use in the manufacture of pharmaceuticals for treating diabetes, ear, nose and throat disorders, epilepsy, genetic disorders, hematological disorders, hormonal disorders, infectious diseases, lymphoma, metabolic disorders, mouth and dental disorders, musculoskeletal disorder, non-malignant disorder, nutritional disorders, pain, rare ophthalmological diseases, rare cancers, rare infectious diseases, rare genetic diseases, rare respiratory diseases, rare central nervous system diseases, rare gastrointestinal diseases, rare immunological diseases, rare cardiovascular diseases, rare dermatological diseases, rare urinary system and sex hormone diseases, rare womens health diseases, rare ear, nose, and throat diseases, animal health disorders, cardiovascular diseases and disorders, central nervous system disorders, dermatologic disorders, endocrine system disorders, gastrointestinal diseases, genito urinary system and sex hormone imbalances, male health disorders, women's health disorders, mental health disorders, musculoskeletal disorders, renal disorders, cancer, ophthalmic disorders, renal diseases, respiratory diseases, trauma and injury
42 Pharmaceutical research services; pharmaceutical drug development services; pharmaceutical design services, namely, shaping and designing pills; testing of pharmaceuticals; conducting clinical trials for others relating to pharmaceuticals and chemicals; pharmaceutical analysis, namely, chemical composition analysis, testing, analysis, and evaluation of pharmaceuticals to determine conformity with certification standards; pharmaceutical laboratory research services relating to pharmaceuticals; pharmaceutical product evaluation; inspection of pharmaceuticals; biological research services; quality control and authentication services for others in the field of pharmaceuticals; information, advice and consultancy services in relation to the aforesaid services

Trademark Events
Nov 29, 2022
Notice Of Registration Confirmation Emailed
Nov 29, 2022
Registered-Principal Register
Sep 13, 2022
Official Gazette Publication Confirmation E-Mailed
Sep 13, 2022
Published For Opposition
Aug 24, 2022
Notification Of Notice Of Publication E-Mailed
Aug 5, 2022
Law Office Publication Review Completed
Aug 2, 2022
Approved For Pub - Principal Register
Aug 2, 2022
Examiner's Amendment Entered
Aug 2, 2022
Notification Of Examiners Amendment E-Mailed
Aug 2, 2022
Examiners Amendment E-Mailed
Aug 2, 2022
Examiners Amendment -Written
Jul 27, 2022
Previous Allowance Count Withdrawn
Jul 27, 2022
Withdrawn From Pub - Examining Attorney Request
Jul 22, 2022
Approved For Pub - Principal Register
Jul 19, 2022
Examiner's Amendment Entered
Jul 19, 2022
Notification Of Examiners Amendment E-Mailed
Jul 19, 2022
Examiners Amendment E-Mailed
Jul 19, 2022
Examiners Amendment -Written
Jun 30, 2022
Teas/Email Correspondence Entered
Jun 30, 2022
Correspondence Received In Law Office
Jun 30, 2022
Teas Request For Reconsideration Received
Jan 24, 2022
Notification Of Final Refusal Emailed
Jan 24, 2022
Final Refusal E-Mailed
Jan 24, 2022
Final Refusal Written
Dec 28, 2021
Teas/Email Correspondence Entered
Dec 28, 2021
Correspondence Received In Law Office
Dec 28, 2021
Assigned To Lie
Dec 23, 2021
Teas Response To Office Action Received
Jun 25, 2021
Notification Of Non-Final Action E-Mailed
Jun 25, 2021
Non-Final Action E-Mailed
Jun 25, 2021
Non-Final Action Written
Jun 21, 2021
Assigned To Examiner
Mar 10, 2021
New Application Office Supplied Data Entered In Tram
Dec 26, 2020
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24